ClinicalTrials.gov record
Completed Phase 3 Interventional

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

ClinicalTrials.gov ID: NCT03204331

Public ClinicalTrials.gov record NCT03204331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain

Study identification

NCT ID
NCT03204331
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Myovant Sciences GmbH
Industry
Enrollment
623 participants

Conditions and interventions

Interventions

  • Estradiol/norethindrone acetate Drug
  • Estradiol/norethindrone acetate placebo Drug
  • Relugolix Drug
  • Relugolix placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2017
Primary completion
Mar 31, 2020
Completion
May 30, 2021
Last update posted
Jun 27, 2021

2017 – 2021

United States locations

U.S. sites
41
U.S. states
21
U.S. cities
39
Facility City State ZIP Site status
Andalusia Andalusia Alabama 36420
Washington DC Washington D.C. District of Columbia 20036
Aventura Aventura Florida 33180
Deland DeLand Florida 32720
Hialeah Hialeah Florida 33012
Hialeah Hialeah Florida 33016
Margate Margate Florida 33063
Miami Miami Florida 33176
Port St. Lucie Port Saint Lucie Florida 34952
Tampa Tampa Florida 33606
Atlanta Atlanta Georgia 30312
Idaho Falls Idaho Falls Idaho 83404
Park Ridge Park Ridge Illinois 60068
Lafayette Lafayette Indiana 47905
Covington Covington Louisiana 70433
Marrero Marrero Louisiana 70072
Towson Towson Maryland 21204
Saginaw Saginaw Michigan 48602
St. Louis St Louis Missouri 63141
Omaha Omaha Nebraska 68124
Albuquerque Albuquerque New Mexico 87102
New York New York New York 10038
New Bern New Bern North Carolina 28562
Akron Akron Ohio 44313
Columbus Columbus Ohio 43231
Columbus Columbus Ohio 43235
Franklin Franklin Ohio 45005
Columbia Columbia South Carolina 29201
Spartanburg Spartanburg South Carolina 29301
Chattanooga Chattanooga Tennessee 37404
Beaumont Beaumont Texas 77702
Corpus Christi Corpus Christi Texas 78412
Dallas Dallas Texas 75231
Fort Worth Fort Worth Texas 76104
Houston Houston Texas 77054
Irving Irving Texas 75062
San Antonio San Antonio Texas 78258
Sugar Land Sugar Land Texas 77479
Pleasant Grove Pleasant Grove Utah 84062
Salt Lake City Salt Lake City Utah 84102
Virginia Beach Virginia Beach Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03204331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03204331 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →